Literature DB >> 8521247

Action of CCK on CDE diet-induced acute pancreatitis in rats treated with hydrocortisone.

M A Manso1, A Rebollo, R Pescador, I de Dios.   

Abstract

The present work studies the effect of previous hydrocortisone administration (10 mg/kg/day) over 7 days on the later development of diet-induced acute pancreatitis in the rat. Acute pancreatitis was induced by feeding a diet deficient in choline and supplemented with 0.5% ethionine (CDE diet) over 10 days. Hydrocortisone pretreatment exacerbated CDE-induced acute pancreatitis. There was a significant increase in serum amylase, pancreatic edema, and haematocrit levels and an insignificant decrease in pancreatic mass in rats pretreated with hydrocortisone. Pancreatic enzyme secretion was strongly reduced in the rats subjected to acute pancreatitis, and although the drop in enzyme levels did not reach statistical significance, the values of secretion were even further reduced in the animals treated with hydrocortisone, pointing to the absence of pancreatic functionality. This effect can be attributed to enzyme storage elicited by previous hydrocortisone administration; activated intracellularly, these enzymes could aggravate the pathology. Administration of the cholecystokinin octapeptide (CCK-8) (10 micrograms/kg/day) during the development of acute pancreatitis in animals pretreated with hydrocortisone substantially improved the general state of the animals' pancreases. There was a significant decrease in serum amylase, pancreatic edema and haematocrit levels in rats injected with CCK, which was accompanied by an increase in pancreatic functionality. Conversely, the administration of L-364,718 (0.1 mg/kg/day), a CCK antagonist, did not improve pancreatic functionality and did not appreciably affect the general state of the organ. It is concluded that in rats with storage levels increased by hydrocortisone administration that are subjected to acute pancreatitis, the secretagogue effect of CCK is more beneficial than the repose of the gland induced by L-364,718.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521247     DOI: 10.1016/0742-8413(95)00045-p

Source DB:  PubMed          Journal:  Comp Biochem Physiol C Pharmacol Toxicol Endocrinol        ISSN: 1367-8280


  7 in total

1.  Hydrocortisone treatment of early SIRS in acute experimental pancreatitis.

Authors:  B Gloor; W Uhl; O Tcholakov; A Roggo; C A Muller; M Worni; M W Büchler
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

2.  Effect of cholecystokinin blockade on the recovery of alterations induced by acute pancreatitis in glycoconjugates of rat zymogen granules.

Authors:  I De Dios; A C Garcia-Montero; A Orfao; M A Manso
Journal:  Glycoconj J       Date:  1998-09       Impact factor: 2.916

3.  The recovery of acute pancreatitis depends on the enzyme amount stored in zymogen granules at early stages.

Authors:  M A Manso; A C García-Montero; M D Tabernero; A Orfao; I De Dios
Journal:  Mol Cell Biochem       Date:  1999-10       Impact factor: 3.396

Review 4.  Pharmacologic therapy for acute pancreatitis.

Authors:  Swetha Kambhampati; Walter Park; Aida Habtezion
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 5.  Do cholecystokinin antagonists increase cytosolic calcium in pancreatic acinar cells and thereby promote pancreatitis?

Authors:  Claus Niederau
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

6.  Cholecystokinin antagonist L364,718 induces alterations in acinar cells that prevent improvement of acute pancreatitis induced by obstruction.

Authors:  Isabel De Dios; Aranzazu Uruñuela; Alberto Orfao; Manuel A Manso
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

7.  Reduced expression of folate transporters in kidney of a rat model of folate oversupplementation.

Authors:  Shilpa Thakur; Som Dev Thakur; Nissar Ahmad Wani; Jyotdeep Kaur
Journal:  Genes Nutr       Date:  2013-12-04       Impact factor: 5.523

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.